Browsing by Author "Tasci I."
Now showing 1 - 4 of 4
Results Per Page
Sort Options
Item Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey - GALATA study(Informa Healthcare, 2015) Ayvaz G.; Keskin L.; Akin T.F.; Dokmetas H.S.; Tasan E.; Ar I.B.; Uren E.; Akber T.; Akdeniz Y.; Bambul N.; Bayraktaroglu T.; Borlu F.; Boz M.; Bozoglu E.; Buyukbese M.A.; Canberk A.; Comlekci A.; Delibasi T.; Demir S.; Eskioglu E.; Guler S.; Gulkan S.; Hekimsoy Z.; Karaca Z.; Keskin M.; Koca N.; Korkmaz H.; Onder E.; Ozisik L.; Peru C.; Sahin M.; Saygili F.; Serin S.; Sezer H.; Sezgin G.; Tasci I.; Tasliyurt T.; Torun A.N.; Tura Bahadir C.; Gursoy Yener G.; Yigit Z.Objective: To evaluate tolerability/safety and the efficacy of the combination of vildagliptin plus metformin in a real-life population of patients with type 2 diabetes mellitus (T2DM). Research design and methods: This multicenter, single-arm, 6 month, observational, prospective cohort study was conducted at 39 centers across Turkey. T2DM patients on vildagliptin and metformin for ≤4 weeks were enrolled regardless of their previous antidiabetic therapy. Main outcome measures: Efficacy was evaluated by measuring hemoglobin A1c (HbA1c) levels. Tolerability/safety parameters evaluated included hypoglycemic events, gastrointestinal events, peripheral edema and weight gain. Results: This study enrolled 665 patients with a mean±standard deviation (SD) age of 55.1±10.2 years and female predominance (n=394, 59.2%). Safety was assessed in all enrolled patients. Hypoglycemia was reported in 10 (1.5%) patients (95% confidence interval = 0.8-2.7%). Efficacy was assessed in 289 (43.5%) patients treated for 6±1 months; these patients showed a mean decrease in HbA1c of 0.8% from baseline value of 7.8% (p<0.001). The percentages of patients who achieved HbA1c targets of ≤6.5% and ≤7.0% were significantly increased, from 10.7% to 33.6% and from 22.1% to 52.6%, respectively (p<0.001 each). The decrease in HbA1c was independent of baseline HbA1c (≤8% vs. 8-10% vs. ≥10%), age (≤65 vs. >65 years) and body mass index (<30 vs. ≥30 kg/m2) (p<0.001 each). In total, 136 adverse events (AEs) were observed in 71 (10.7%) patients; 10 (1.5%) patients experienced hypoglycemia and gastrointestinal AEs were most commonly reported (n=29, 4.4%). Conclusions: In a 'real-life' setting, the vildagliptin and metformin combination was associated with significant improvements in reaching target HbA1c levels, even in elderly and obese patients with T2DM. Moreover, vildagliptin and metformin demonstrated a good overall tolerability/safety profile. © 2015 All rights reserved: reproduction in whole or part not permitted.Item Reversible lesion of the corpus callosum associated with COVID-19: A case report(ASEAN Neurological Association, 2021) Gemici Y.I.; Tasci I.Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may affect the central nervous system and peripheral nervous system. Major central nervous system manifestations of SARS-CoV-2 infection include seizures, meningoencephalitis, ischemic stroke, anosmia, and hypogeusia. The reversible splenial lesion syndrome was first described in 2004. Although reversible splenial lesion syndrome was initially recognized as a benign phenomenon, a second type of reversible splenial lesion syndrome was identified in later years, which has a poorer prognosis and potentially serious sequela. Reversible splenial lesion syndrome can be caused by numerous etiologies including viruses. In this report, we present a rare case of COVID-19 with reversible splenial lesion, who presented with ataxia and dizziness. © 2021, ASEAN Neurological Association. All rights reserved.Item Epigenetic analysis of heat shock activator complex in the peripheral blood of Parkinson's disease patients and its clinical significance(Turkish Neurosurgical Society, 2024) İnalkac Gemici Y.; Tasci I.; Dundar M.; Ozgen N.; Danis N.; Gozde Gozukara H.; Koc A.Objectives: This study aimed to investigate the methylation changes of related genes in the peripheral blood and their clinical significance in Parkinson's disease (PD) and whether the methylation change of the gene encoding long noncoding RNA was different in the blood of patients and controls. Patients and methods: This prospective cross-sectional, controlled study was conducted with 45 participants (22 males, 23 females; mean age: 60.7±5.9 years; range, 53 to 75 years) between June 2020 and June 2021. Drug-naive patients diagnosed with PD were included in this study. Those with PD and a Mini-Mental State Examination (MMSE) score >23 were defined as Group 1 (n=15), and those with PD and an MMSE score ≤23 were defined as Group 2 (n=15). Controls were included in Group 3 (n=15). The methylation changes of genes HSP70, HSP90, heat shock factor 1 (HSF1), heat shock RNA 1 (HSR1), and eukaryotic translation elongation factor 1 alpha (eEF1a) were investigated with methylation-specific real-time quantitative polymerase chain reaction analysis. Results: The eEF1a was significantly more hypermethylated in Group 1. In Group 2, HSP70, HSP90 HSF1, HSR1, and eEF1a were significantly hypomethylated compared to Group 1 and Group 3 (for all genes p<0.001). The HSF1 hypomethylation was negatively correlated with MMSE and positively correlated with depression scores (p=0.03 and p=0.013, respectively). The correlation of eEF1a with MMSE and depression was the opposite of HSF1 (p<0.001 and p=0.013, respectively). Conclusion: Cell line and autopsy studies indicate that eEF1a hypermethylation might be one of the main molecules triggering alpha-synuclein aggregation in the pathogenesis of PD. Therefore, eEF1a may be a molecule that can be used as a peripheral biomarker. The findings supported this idea as it was more hypermethylated in PD patients than in controls, whereas its negative regulator HSF1 was hypomethylated and correlated with the clinic. Furthermore, the worsening of cognitive functions and depression in PD patients may affect methylation levels of chaperone genes in the peripheral blood. © 2024 by the Turkish Neurological Society.Item Possible bradykinesia occurrence in lymphocyte division in Parkinson's disease(Ondokuz Mayis Universitesi, 2024) Inalkac Gemici Y.; Tasci I.; Dundar M.; Ozgen N.; Gozde Gozukara H.; Koc A.Lymphocytes have dopamine receptors, and low dopamine levels increase receptor synthesis. Lymphocytes may move slower in Parkinson's, which is characterized by low dopamine levels. We hypothesized that longer telomeres would indicate less lymphocyte division. We investigated whether leukocyte telomere length (LTL) is different in naïve Parkinson’s disease (PD) patients and whether telomere length has clinical significance in determining telomere length in naïve Parkinson's patients. Naïve patients diagnosed with PD were included in this study. 29 naïve PD patients and 15 controls were included in the study. Subgroup analyses were performed according to MMSE and depression scores of PD patients. LTL was measured by RT-qPCR. Differences in LTL between the groups were examined. Clinical and demographic findings and LTL were examined and correlated using appropriate statistical methods. Forty-four participants meeting the inclusion criteria were included in the study. LTL was significantly longer in PD patients than in the control group (p = 0.043) and was positively correlated with clinical worsening of the disease. According to the Analysis of Moment Structures, evaluation total MMSE was 1.82, UPDRS was -1.53, and depression score was -.31 negatively correlated with telomere. LTL was found to be longer in naïve PD patients than in controls. Without other factors that could affect telomere; these findings support the hypothesis that leukocyte division could be slower in PD than the control group at the same age. Additional studies are needed on this subject. Additionally, a longer TL could be a marker for a better clinical course in PD. © 2024 Ondokuz Mayis Universitesi. All rights reserved.